Relevium Medical

What Relevium Medical does

Relevium Medical is a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the University of Galway Bioinnovate programme, headquartered in Galway, Ireland with a presence in the United States. The company develops a pipeline of novel pharmacological hydrogel treatments that integrate natural biopolymers with pharmacologically active agents to address chronic pain conditions. Its lead candidate, RM-010, is an injectable intra-articular hydrogel targeting moderate-to-severe knee osteoarthritis, designed to provide up to six months of sustained pain relief, joint lubrication, and local administration, positioning it as an alternative to short-acting corticosteroid injections, oral NSAIDs, and opioid-based regimens. The pipeline extends the platform to three additional indications: RM-020 for interstitial cystitis (bladder lining replacement with nerve pain suppression), RM-030 (broad-spectrum antimicrobial gel for trauma wound infections with integrated pain reduction), and RM-040 (post-surgical pain hydrogel intended to reduce reliance on oral opioids).

The company's go-to-market model, once products are approved, is enterprise field sales to orthopedic specialists, rheumatologists, and pain management physicians through healthcare-provider and clinical distribution channels integrating RM-010 into existing knee OA treatment pathways. Revenue mechanics are described as one-time pharmaceutical product sales upon regulatory authorization; the company is currently pre-revenue. The core team of approximately nine members includes CEO and co-founder Alison Liddy (BSc, MSc, PhD, Bioinnovate fellow), Scientific Advisor Martin O'Halloran (Executive Director of Bioinnovate Ireland, 20+ medtech patents, 7 successive ERC awards), CFO Damien Kelly (former CFO of Mylan Global and MD of Bioniche), Commercialisation Advisor Kevin McDonagh, two Principal Scientists, a Senior Research Chemist, and a Development Chemist, supplemented by four clinical advisors from Stanford Medicine, MSK Doctors UK, University Hospitals Cleveland, and Bon Secours Hospital Galway. Funding to date includes a €2.4 million EIC Transition Grant (Project #101058000, 2022-2024) with University of Galway, $500,000 from Y Combinator and Enterprise Ireland (August 2022), and approximately $4.86 million from Ireland's Disruptive Technologies Innovation Fund (November 2024).

Name

Relevium Medical

Legal name

Relevium Medical

Website

https://relevium-medical.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Relevium Medical is a clinical-stage biopharmaceutical company developing a pipeline of injectable pharmacological hydrogel treatments for chronic pain conditions, including lead candidate RM-010 for knee osteoarthritis, serving healthcare professionals and osteoarthritis, interstitial cystitis, wound infection, and post-surgical pain patients.

Ownership category

akta.pro rank

Product category

Pain Therapeutics / Osteoarthritis Pharmaceuticals

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Biopharmaceutical treatments
• Osteoarthritis therapy
• Pharmacological hydrogels
• Chronic pain therapeutics
• Injectable drug delivery

Headquarters

HQ city

Galway

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue biopharmaceutical company developing a pipeline of novel pharmacological hydrogel treatments. Revenue expected from sale of injectable therapeutic products upon regulatory approval. Lead candidate RM-010 targets osteoarthritis pain market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Relevium Medical develops and commercializes a pipeline of novel pharmacological hydrogel therapeutics for chronic pain conditions. Its lead product, RM-010, is an injectable intra-articular hydrogel for moderate to severe knee osteoarthritis providing up to 6 months of pain relief and lubrication. Additional candidates target interstitial cystitis (RM-020), trauma wound infections with antimicrobial action (RM-030), and post-surgical pain to reduce opioid use (RM-040). The company sells its products (future, post-approval) to healthcare professionals and clinical channels.

Product overview

Relevium Medical is a biopharmaceutical company developing a pipeline of novel pharmacological hydrogel treatments for chronic pain conditions. The portfolio includes four distinct candidates: RM-010 (lead injectable hydrogel for osteoarthritis, serving as a platform product extensible to other joints), RM-020 (gel for interstitial cystitis acting as bladder lining replacement), RM-030 (multimodal antimicrobial gel for trauma wound infections), and RM-040 (post-surgical pain relief hydrogel). The company's science integrates natural biopolymers with pharmacologically active agents to create tailored treatments offering superior efficacy versus existing options.

Differentiator

Problem solved

Functional benefit

Products and services

• RM-010 Hydrogel

Quantifiable outcome

• RM-010 provides 6 months of sustained pain relief versus short-acting corticosteroids and oral medications
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• University of GalwaycoreStrategic or Co-development PartnerSpinout from University of Galway Bioinnovate programme. Collaborative partner on EIC Transition Grant for ARTRIGEL project. Provides research facilities, academic expertise, and continued R&D collaboration. Martin O'Halloran is Executive Director of BioInnovate programme at University of Galway.
• Health Innovation Hub IrelandsupportingStrategic or Co-development PartnerIrish health innovation support organisation connecting innovative healthcare solutions with the health system. Listed as partner supporting market access and healthcare ecosystem integration.
• Bioinnovate IrelandcoreStrategic or Co-development PartnerEurope's only affiliate of Stanford's BioDesign programme. Martin O'Halloran is Executive Director. Company is a spinout from this programme which provides innovation methodology and network.
• Stanford MedicinesupportingStrategic or Co-development PartnerClinical advisor Prof Peter Schmidt serves as Clinical Professor of Anaesthesiology, Perioperative and Pain Medicine at Stanford Medicine. Provides scientific and clinical expertise.
• MSK Doctors UKsupportingStrategic or Co-development PartnerClinical advisor Prof Paul Lee serves as Regeneration and Sports Doctor, Knee and Hip Consultant. Provides clinical expertise and potential market access.
• University Hospitals Cleveland Medical CentersupportingStrategic or Co-development PartnerClinical advisor Prof Salim Hayek serves as Chief of Division of Pain Medicine and Professor at University Hospitals and Case Western Reserve University. Provides clinical expertise.
• Bon Secours Hospital GalwaysupportingStrategic or Co-development PartnerClinical advisor Prof Stephen Kearns serves as Consultant Orthopaedic Surgeon and Honorary Lecturer. Provides clinical expertise and Ireland market access.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Pacira BioSciences: Developer of EXPAREL and acquirer of Flexion Therapeutics (ZILRETTA, an extended-release intra-articular corticosteroid for OA pain). Most directly comparable as a non-opioid injectable pain franchise targeting the same orthopedic surgeon and pain medicine prescriber base as RM-010.
• Centrexion Therapeutics: Clinical-stage company developing non-opioid treatments for chronic pain conditions including OA knee pain (CNTX-4975) — comparable as a clinical-stage chronic pain biotech targeting the same unmet need and prescriber channel.
• Bioventus: Specialty orthobiologics company with a leading portfolio of intra-articular knee OA treatments including hyaluronic acid viscosupplements (DUROLANE, GELSYN-3) — the most directly comparable competitor to Relevium's RM-010 in terms of indication, route of administration, and prescriber base.
• Anika Therapeutics: Developer of hyaluronic acid-based viscosupplements (e.g., MONOVISC, ORTHOVISC) for knee OA pain — competes in the same intra-articular injection market with an established US and international commercial footprint.
• Flexion Therapeutics: Pre-acquisition developer of ZILRETTA (triamcinolone acetonide extended-release), the first FDA-approved long-acting intra-articular steroid for knee OA — provides a direct analog for clinical, regulatory, and commercial pathway for RM-010.
• Eupraxia Pharmaceuticals: Clinical-stage biotech developing EP-104IAR, a long-acting intra-articular fluticasone formulation for knee OA — directly comparable to RM-010 in modality (local, sustained-release injectable), indication, and target patient population.

Regional players

• Seikagaku Corporation: Japan-based specialty pharma with a leading portfolio of hyaluronic acid viscosupplements for knee OA (SUPARTZ, Gel-One) — comparable intra-articular OA franchise primarily serving the Japanese and Asian market where Relevium has limited footprint.

Emerging players

• Moebius Medical: Emerging clinical-stage company developing a novel non-steroid, non-opioid intra-articular therapy for knee OA — comparable as a smaller, similarly positioned early-stage innovator addressing the same RM-010 indication with a different delivery modality.
• OrthoTrophix: Clinical-stage biotech developing disease-modifying OA drugs (DMOADs) including intra-articular TPX-100 — overlapping chronic OA treatment pipeline with focus on cartilage preservation, partially overlapping RM-010's mechanism.

Broad incumbents

• Grünenthal: Major European pain-focused pharmaceutical company with a broad chronic pain portfolio and active interest in novel non-opioid pain therapeutics — represents a likely strategic partner or acquirer profile for Relevium at clinical inflection points.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/relevium-medical
• Xx.com/ReleviumMed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Relevium Medical